"For the primary endpoint, all dose groups of BTX 1503 reduced the number of inflammatory lesions from baseline with the highest efficacy obtained for the 5% BTX 1503 QD group (-11.8 lesions). This corresponds to an average percent reduction of 40.54%. The combined vehicle group result was -11.3 lesions or an average percent reduction of 40.15%."
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.015(10.7%) |
Mkt cap ! $303.9M | |||
| Open | High | Low | Value | Volume |
| 14.5¢ | 15.5¢ | 14.3¢ | $2.902M | 19.36M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 583208 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 2683129 | 48 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |